Pupillary biomarkers method assesses psychotropic drug effectiveness
Summary
USPTO published patent application US20260094684A1 for a method of assessing psychotropic drug effectiveness using pupillary biomarkers. The method uses a pupilometer to obtain and compare pupillary data before and after drug administration, displaying an output indicating drug effectiveness. Inventors: Kamran Siminou, Claudio Privtera, Jeffrey Oliver. Application No. 18898899.
What changed
USPTO published a patent application (US20260094684A1) for a method of assessing the effectiveness of psychotropic drugs using pupillary biomarkers. The method involves obtaining pupillary data from a subject before and after drug administration using a pupilometer, processing the data, and displaying an output indicating effectiveness. CPC Classifications include G16H 20/10 (ICT for pharmaceuticals), A61B 3/112 (pupillometers), and A61B 3/14 (eye examination devices). The application was filed on 2024-09-27.
This patent application does not create regulatory obligations for pharmaceutical manufacturers or healthcare providers. It is informational, indicating that a method for assessing psychotropic drug effectiveness via pupillary biomarkers has been invented and published. Companies developing psychotropic medications or pupilometer devices may wish to review this application to assess potential patent landscape implications. No compliance deadlines or penalties are associated with this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PUPILLARY BIOMARKERS TO ASSESS EFFECTS OF PSYCHOTROPIC DRUGS
Application US20260094684A1 Kind: A1 Apr 02, 2026
Inventors
Kamran Siminou, Claudio Privitera, Jeffrey Oliver
Abstract
A method of assessing the effectiveness of a psychotropic drug on a mammalian subject is described. The method includes providing a pupilometer having a display, using the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject before the subject is administered the psychotropic drug, using the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject after the subject is administered the psychotropic drug, using the pupilometer to process all of the pupillary biomarker data, and displaying an output on the display of the pupilometer that indicates the effectiveness of the psychotropic drug.
CPC Classifications
G16H 20/10 A61B 3/112 A61B 3/14
Filing Date
2024-09-27
Application No.
18898899
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Health Informatics (G16H)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Health Informatics (G16H) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.